Pregabalin: Nursing Drug Guide, Renal Dosing & NCLEX Review
Pregabalin is renally eliminated with a short half-life, so under-dosing is not the only error—giving a standard adult dose when creatinine clearance has fallen causes accumulation, dizziness, and somnolence. With opioids or other CNS depressants, respiratory depression can be serious or fatal; angioedema and antiepileptic mood warnings also need bedside vigilance before every dose.
Pregabalin is eliminated primarily by renal excretion—dose-dependent dizziness and somnolence worsen when creatinine clearance is low and the MAR dose is not adjusted per Table 2. Co-prescription with opioids or other CNS depressants, or use in patients with underlying respiratory impairment, has been associated with serious, life-threatening, or fatal respiratory depression; monitor for difficulty breathing, sedation, RR, and SpO2. Angioedema (face, mouth, neck) can be life-threatening—discontinue immediately if swelling or airway compromise occurs. Antiepileptic drugs including pregabalin increase suicidal thoughts or behavior risk; do not stop abruptly—taper over at least 1 week per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: match the order to creatinine clearance (not just the indication), scan for opioids and other CNS depressants, and assess alertness, gait, and breathing. If therapy ends, confirm a gradual taper—not an abrupt stop—and watch mood and behavior per antiepileptic drug warnings.
Most common brand names
Pregabalin is available as generic capsules and oral solution; the reference brand is Lyrica (capsules and oral solution). Lyrica CR is an extended-release formulation with different dosing—do not substitute for immediate-release pregabalin without prescriber/pharmacy direction.
Verify you are dispensing pregabalin, not gabapentin (Neurontin) or gabapentin enacarbil (Horizant/Gralise). Pregabalin is a Schedule IV controlled substance in the U.S. per reviewed labeling—follow institutional controlled-substance policies.
Why we give it — Indications
Pregabalin is indicated for neuropathic pain (including after shingles and in diabetic peripheral neuropathy), fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for partial-onset seizures in patients 1 month of age and older with epilepsy.
| Use | Detail |
|---|---|
| Diabetic peripheral neuropathy (adults) | Begin 150 mg/day (e.g., 50 mg TID); maximum recommended 300 mg/day when CrCl ≥60 mL/min; doses above 300 mg/day not recommended per labeling. |
| Postherpetic neuralgia (adults) | Begin 150 mg/day; titrate to 300 mg/day within 1 week; may increase up to 600 mg/day in selected patients who tolerate 300 mg/day. |
| Fibromyalgia (adults) | Recommended 300–450 mg/day; begin 150 mg/day; doses above 450 mg/day not recommended per labeling. |
| Spinal cord injury neuropathic pain | 150–600 mg/day range; start 150 mg/day and titrate based on response and tolerability. |
| Partial-onset seizures (adjunct) | Adults: begin 150 mg/day, maximum 600 mg/day in 2–3 divided doses; pediatric weight-based dosing per Table 1 in labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak (oral) | Within 1.5 hours under fasting conditions | Reassess sedation and pain response after peak; timing matters when co-administering sedatives |
| Half-life | About 6 hours (mean 6.3 h) with normal renal function; elimination nearly proportional to CrCl | Renal dysfunction prolongs exposure; adjust dose per Table 2 and monitor CNS effects |
| Elimination | Renal excretion as unchanged drug (<2% metabolized); supplemental dose after hemodialysis per Table 2 | Check renal function before giving; coordinate HD supplemental doses with pharmacy |
| Steady state | Within 24–48 hours with repeated dosing | Expect increasing sedation during early titration; reassess after steady state |
On a small screen, swipe or scroll sideways to see the full table.
Pregabalin binds with high affinity to the α2δ auxiliary subunit of voltage-gated calcium channels in CNS tissues. Although the full mechanism is not elucidated, this binding is thought to reduce calcium-dependent release of pro-nociceptive neurotransmitters and contribute to antiseizure and analgesic effects. Because pregabalin undergoes negligible metabolism and is renally eliminated unchanged, nursing monitoring centers on creatinine clearance, dose-dependent CNS effects, and sedative co-therapy—not hepatic pathways.
Dosing overview
Dosing depends on indication, age, and renal function. Always verify the current order against creatinine clearance or eGFR and official Table 2 renal adjustment. Dosing must be verified against current prescribing information, prescriber order, renal function, and local policy.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber/pharmacy for guidance if a dose is missed, especially when seizure control depends on consistent levels.
Before you give it — Safety check
Pretreatment checks
- Confirm indication (neuropathic pain, fibromyalgia, or seizure adjunct) and that the ordered total daily dose matches creatinine clearance using Table 2—not the “normal renal” dose on a falling eGFR.
- Review sedative load: opioids (e.g., morphine, oxycodone), benzodiazepines, and other CNS depressants increase respiratory depression risk.
- Screen for duplicate gabapentinoid therapy (pregabalin plus gabapentin); efficacy of adjunctive pregabalin with gabapentin has not been evaluated in controlled trials per labeling.
- Assess allergy history, prior angioedema (including with ACE inhibitors), baseline alertness, gait, and respiratory status (RR, SpO2).
Contraindications
- Known hypersensitivity to pregabalin or any component of the formulation (angioedema and hypersensitivity reactions have occurred).
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Opioids and other CNS depressants | Serious, life-threatening, or fatal respiratory depression reported with opioids; additive sedation with CNS depressants including oxycodone and lorazepam in studies | Monitor RR, SpO2, and sedation; consider lower starting dose; hold and escalate if compromise; reduce or withdraw CNS depressants per prescriber |
| Thiazolidinedione antidiabetic agents | Higher rates of peripheral edema and weight gain when combined with pregabalin | Monitor weight and edema; notify prescriber if rapid gain or functional edema; common in diabetic neuropathy patients |
| ACE inhibitors and other angioedema-associated drugs | Increased angioedema risk in patients with prior angioedema or on ACE inhibitors | Teach swelling/airway warning signs; discontinue pregabalin immediately if angioedema suspected |
| Gabapentin | Adjunctive pregabalin with gabapentin not evaluated in controlled trials; no combined dosing recommendations | Clarify duplicate therapy with pharmacy; monitor for excess CNS depression if both are ordered |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral — capsules (25–300 mg) or oral solution (20 mg/mL). May take with or without food per labeling.
- Swallow capsules whole with water unless prescriber/pharmacy directs otherwise; use a calibrated oral syringe for solution.
- Distribute total daily dose in two or three divided doses per order (BID/TID) and indication.
- Perform medication reconciliation to prevent duplicate gabapentinoid or sedative stacking; verify Schedule IV controlled-substance procedures per facility policy.
- Dispense the FDA-approved Medication Guide when required per labeling and local policy.
If pregabalin is reduced or discontinued, taper gradually over a minimum of 1 week per labeling. Abrupt or rapid discontinuation can increase seizure risk and cause withdrawal symptoms (insomnia, nausea, headache, anxiety); suicidal behavior or ideation has been reported after discontinuation.
Expected therapeutic response
- Decreased neuropathic pain intensity or improved function with titration over days to weeks—not immediate opioid-like relief.
- Improved fibromyalgia symptoms or reduced partial-seizure frequency when used as adjunctive antiepileptic therapy.
- Acceptable sedation without respiratory compromise; if pain, function, or seizures worsen despite adherence, notify prescriber rather than self-escalating dose.
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dizziness, somnolence, dry mouth | Most common (≥5% and at least twice placebo): dizziness ~30%, somnolence ~23% in adult trials; dose-related | Assess sedation, ataxia, and fall risk; hold if excessive CNS depression; avoid sedative stacking without prescriber review |
| Peripheral edema, blurred vision, weight gain | Common; edema higher with thiazolidinedione co-therapy per labeling | Monitor weight and edema; notify prescriber if rapid gain or limiting edema; reinforce diabetic foot/skin care when relevant |
| Thinking abnormal (concentration/attention) | Common per labeling | Assess safety for driving and complex tasks; document cognitive complaints |
| Angioedema / hypersensitivity | Serious; life-threatening respiratory compromise reported | Discontinue pregabalin immediately; treat airway emergency per protocol; never rechallenge |
| Respiratory depression | Serious, life-threatening, or fatal—especially with CNS depressants or underlying respiratory impairment | Hold dose, monitor RR/SpO2, reduce or withdraw CNS depressants per prescriber; emergency escalation if compromise |
| Suicidal thoughts or behavior | Increased risk with antiepileptic drugs including pregabalin (pooled AED analysis per labeling) | Monitor mood and behavior; report new or worsening depression, agitation, or self-harm thoughts immediately |
| Withdrawal symptoms / seizure risk | Reported after abrupt or rapid discontinuation | Taper over minimum 1 week; clarify plan with prescriber/pharmacy before stopping |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Postmarketing overdose reports include reduced consciousness, depression/anxiety, confusional state, agitation, restlessness, seizures, and heart block. Deaths have been reported with lone pregabalin overdose and with other CNS depressants. Patients may present with altered mental status, somnolence, and respiratory depression.
Antidote
No specific antidote is listed in the reviewed prescribing information; management is supportive and guided by poison control or toxicology services per facility protocol and local emergency guidance. General supportive care includes vital sign monitoring; emesis or gastric lavage may be considered if indicated per toxicology guidance.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol. Monitor airway, breathing, circulation, and level of consciousness continuously until the patient is stable.
Look-alike / sound-alike and error prevention
- Pregabalin vs pregabalin (Lyrica) — both treat neuropathic pain; verify correct drug, dose, and frequency on every pass
- Immediate-release pregabalin vs Lyrica CR — different formulations and schedules; do not substitute without prescriber/pharmacy approval
- Strength confusion — capsules (100/300/400 mg) vs tablets (600/800 mg) vs oral solution (250 mg/5 mL); read label strength and total daily dose aloud during independent check
- Lyrica brand imprints — capsules may print “Lyrica/” on cap; still verify generic name and strength
- Duplicate therapy — pregabalin plus pregabalin or multiple sedating agents increases CNS and respiratory depression risk
- Renal dose errors — standard TID dosing in declining renal function is a common inpatient medication error; confirm creatinine clearance or eGFR before administration
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Capsules: swallow whole with water unless pharmacy provides alternate instructions. Oral solution: measure with calibrated device (20 mg/mL). |
| Food timing | May be taken with or without food per labeling. |
| Renal labs | Recheck creatinine/eGFR when hydration changes, contrast exposure, or new AKI—request pharmacy Table 2 review before next dose. |
| Hemodialysis | Maintenance dose by CrCl plus single supplemental dose immediately after each 4-hour HD session per Table 2—coordinate with pharmacy. |
| Taper | Taper gradually over a minimum of 1 week when discontinuing or reducing per labeling. |
| Commonly missed | Renal adjustment after AKI, opioid/benzodiazepine stacking, TZD-related edema monitoring, and abrupt stop orders in seizure patients. |
| Ask pharmacy when | Unclear renal dose, hemodialysis supplemental dose timing, enteral tube administration, or interacting sedative combinations. |
On a small screen, swipe or scroll sideways to see the full table.
Red flags — Stop and act
Pregabalin red flags span angioedema, respiratory depression with sedatives, renal accumulation, and mood or withdrawal risk after rapid stops.
- Facial, mouth, tongue, or neck swelling with or without difficulty breathing — angioedema; discontinue pregabalin immediately and escalate
- RR <12, SpO2 drop, or difficult to arouse — suspect respiratory depression, especially with opioids or other CNS depressants
- Hives, dyspnea, or wheezing shortly after a dose — hypersensitivity; discontinue and evaluate urgently
- New or worsening depression, agitation, or suicidal thoughts — antiepileptic drug class warning; notify prescriber same day
- Breakthrough seizures, severe confusion, or agitation after abrupt dose changes — clarify taper and seizure rescue plan with prescriber
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment / hemodialysis | Pregabalin elimination is nearly proportional to CrCl; dose-dependent adverse reactions increase when doses are not reduced. Adjust per Table 2; HD patients need supplemental dose after dialysis. |
| Older adults | Age-related renal decline increases exposure; higher dizziness, somnolence, and fall risk; start low, renal-adjust, and monitor gait and sedation. |
| Patients on opioids or with respiratory disease | Highest-risk group for fatal respiratory depression; monitor RR/SpO2 and sedation closely; consider lower starting dose when co-prescribed. |
| Diabetes on thiazolidinediones | Higher peripheral edema and weight gain when pregabalin is combined with TZDs—monitor closely in diabetic neuropathy patients. |
| Pregnancy | Observational data suggest possible small increase in major birth defects without a consistent pattern; extended gabapentinoid use with opioids near delivery may increase neonatal withdrawal risk per labeling. Use only if benefit outweighs risk. |
| Lactation | Pregabalin detected in breast milk (~76% of maternal plasma concentrations in a study); manufacturer recommends breastfeeding is not recommended during treatment due to potential tumorigenicity risk in animal data. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function (serum creatinine, eGFR/CrCl) before initiation and when clinical status changes—especially after AKI or dehydration.
- Sedation, gait, dizziness, RR, SpO2, weight, peripheral edema, and pain/seizure control; use structured pain assessment and neurological assessment.
- Mood, behavior, and suicidal ideation per antiepileptic drug class warning; edema and weight in older adults.
Document
- Dose, route, time, indication, renal function used for verification, and sedative co-medications reviewed.
- Patient response: pain score, seizure activity, sedation level, RR/SpO2, and adverse effects.
- Hold/escalation actions, prescriber/pharmacy notifications, taper instructions, and patient teaching provided.
Patient teaching
- Take exactly as prescribed in divided doses; do not stop suddenly—ask how to taper if therapy ends.
- Pregabalin may cause drowsiness, dizziness, and blurred vision; do not drive or operate machinery until you know how it affects you.
- Avoid alcohol and do not start/stop opioids, sleep medicines, or benzodiazepines without prescriber guidance.
- Report trouble breathing, swelling of face/lips/tongue/throat, hives, wheezing, worsening mood, or suicidal thoughts immediately.
- Report rapid leg swelling or weight gain, especially if you take a thiazolidinedione diabetes medicine.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity or current angioedema/hypersensitivity symptoms (swelling, hives, wheezing).
- Suspected respiratory depression (RR <12, SpO2 below baseline, or difficult to arouse)—especially with opioid co-therapy.
- Ordered dose exceeds renal adjustment for current CrCl/eGFR until pharmacy/prescriber clarifies.
- New or rapidly worsening confusion, agitation, or suicidal ideation until assessed.
- Duplicate gabapentinoid therapy (pregabalin plus gabapentin) or unclear taper/stop order in a patient with seizures.
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Pregabalin is common on chronic pain, neurology, and rehabilitation MARs. The highest-yield nursing checks are creatinine clearance–matched dosing, sedative and opioid stacking review, angioedema vigilance, and safe taper planning—not routine oral administration alone.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and time—with independent double-check of capsule strength (25–300 mg) or solution concentration.
- Renal function supports the ordered total daily dose per Table 2; contact pharmacy if CrCl <60 mL/min and no adjustment documented.
- Review PRN opioids, benzodiazepines, and home sedatives; assess baseline RR, SpO2, and sedation score.
- Confirm no duplicate gabapentinoid therapy and that discontinuation orders include a taper when clinically appropriate.
2. High-alert and safety badge
Not on standard high-alert lists — Schedule IV controlled substance with renal and respiratory risksPregabalin is DEA Schedule IV per U.S. labeling. CNS depression, respiratory depression with opioids, dose-dependent sedation, and renal accumulation make focused independent checks worthwhile even when it is not on institutional high-alert lists.
3. Clinical workflow: hold and question rules
- If sedation exceeds baseline or RR falls after a dose, hold subsequent doses and escalate before the next scheduled administration.
- If creatinine rises or eGFR falls during admission, request pharmacy renal dose review before giving the next dose.
- If prescriber orders immediate discontinuation in a patient with epilepsy, clarify taper duration (minimum 1 week per labeling) before executing.
4. Critical teach-back questions
- “What should you do if you want to stop pregabalin?” Do not stop abruptly; call the prescriber for taper instructions over at least 1 week—especially if taken for seizures.
- “When should you seek emergency care?” Trouble breathing, facial/throat/tongue swelling, hives with wheezing, or thoughts of self-harm.
5. Care coordination
Prescriber / neurology: Clarify indication, target dose, taper plans, and seizure rescue when pregabalin is used for epilepsy or complex neuropathic pain.
Pharmacist: Table 2 renal adjustment, hemodialysis supplemental dosing, sedative interaction review, and pregabalin vs gabapentin or Lyrica CR verification.
🧠 Quick mental checklist
- Does creatinine clearance support this total daily dose per Table 2?
- Any opioids, benzodiazepines, or duplicate gabapentinoids on the MAR?
- Any facial or throat swelling, hives, or wheeze since the last dose?
- Are RR, SpO2, and alertness acceptable before I give this?
- If stopping or reducing, is there a taper plan (minimum 1 week)?
Pregabalin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for pregabalin: priority actions after reviewing the case tabs (MAR, labs, vitals, nursing notes), sedative-interaction SATA, renal/sedation trend interpretation, matrix urgency matching, taper judgment, and documentation cloze—centered on renal dose adjustment, CNS depression, and respiratory risk with opioid co-therapy.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
0800 — Pregabalin 75 mg PO BID (fibromyalgia; started 5 days ago)
PRN — Oxycodone 5 mg PO q6h severe pain (1 dose given 0600)
Scheduled — Pioglitazone 30 mg PO daily
Home med list (not yet reconciled): Gabapentin 300 mg TID
Renal panel trend
Creatinine: 1.3 mg/dL (baseline) → 1.6 → 1.9 mg/dL today
Calculated CrCl: ~52 → 38 mL/min
eGFR: ~48 → 36 mL/min/1.73 m²
Pharmacy note: renal dose review requested—no adjustment on MAR
Vitals (last 4 h)
BP 104/58 mmHg
HR 92/min
RR: 15 → 12 → 10/min
SpO2: 95% → 93% → 92% on room air
Temp 36.7 °C
Pain 6/10; patient very drowsy, slow responses
66-year-old with fibromyalgia and type 2 diabetes. Reports lip tingling after morning dose—no swelling documented yet. Unsteady ambulation after oxycodone. Night nurse gave pregabalin despite documented somnolence. Patient still taking home gabapentin per family. Prescriber ordered “stop pregabalin today” without taper; patient also uses pregabalin as adjunct for partial seizures.
Answer key & rationale
Frequently asked questions
Can pregabalin be given with morphine or other opioids?
It may be co-prescribed, but labeling warns of increased pregabalin levels with morphine and additive CNS and respiratory depression with opioids. Monitor sedation, respiratory rate, and oxygenation closely; consider a lower starting dose and hold/escalate if compromise occurs.
How should pregabalin be adjusted for renal impairment?
Dose reduction is required based on creatinine clearance using the official renal adjustment table—for example, lower total daily doses and less frequent regimens as CrCl falls. Hemodialysis patients need maintenance doses based on CrCl plus a supplemental dose after dialysis per labeling.
Why can pregabalin not be stopped abruptly?
Abrupt discontinuation can increase seizure frequency in patients with seizure disorders and has been associated with withdrawal symptoms (agitation, disorientation, confusion) after high doses. Labeling recommends tapering over at least 1 week when reducing or stopping.
What adverse effects should patients report right away?
Seek urgent care for trouble breathing, facial or throat swelling, severe rash with fever, unusual bruising or multiorgan symptoms, worsening mood, or suicidal thoughts. Report excessive sleepiness, falls, or confusion to the care team promptly.
Can pregabalin be taken with gabapentin?
Labeling states that adjunctive pregabalin with gabapentin has not been evaluated in controlled trials and provides no combined-dosing recommendations. Avoid duplicate gabapentinoid therapy unless the prescriber documents a clear rationale; monitor closely for excess sedation and respiratory depression.
References
-
U.S. National Library of Medicine. LYRICA (pregabalin) capsules and oral solution — prescribing information. DailyMed (Viatris Specialty LLC; revised April 2025).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9
-
U.S. Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). Drug Safety Communication (2019).https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
-
National Institutes of Health. Pregabalin. Drugs and Lactation Database (LactMed). Updated November 2024.https://www.ncbi.nlm.nih.gov/books/NBK501821/
-
U.S. National Library of Medicine. Pregabalin. MedlinePlus.https://medlineplus.gov/druginfo/meds/a605045.html
-
National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical guideline CG173.https://www.nice.org.uk/guidance/cg173
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.